Spots Global Cancer Trial Database for Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
Official Title: An Open Non-randomized Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Tarceva in Combination With Capecitabine in Patients With Advanced Pancreatic Cancer
Study ID: NCT00873353
Interventions
Study Description
Brief Summary: The purpose of this study is to determine efficacy of the treatment with erlotinib in combination with capecitabine in patients with advanced pancreatic cancer.
Detailed Description: This efficacy will be determined by objective response rate following RECIST criteria.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Arquitecto Marcide, Ferrol, La Coruña, Spain
Complejo Hospitalario Universitario de La Coruña, La Coruña, , Spain
Centro Oncológico de Galicia, La Coruña, , Spain
Complejo Hospitalario Xeral Calde, Lugo, , Spain
Complejo Hospitalario de Orense, Orense, , Spain
Hospital do Meixoeiro, Vigo, , Spain
Complejo Hospitalario Xeral Cies, Vigo, , Spain
Hospital POVISA, Vigo, , Spain
Contact Details
Name: Rafel López López, Coordinator
Affiliation: Grupo Gallego de Investigaciones Oncológicas
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
